Company news

AstraZeneca PLC news in 2023

AstraZeneca PLC's news releases, calls and decks from 2023, newest first.

View company

AstraZeneca acquires Gracell

December 27, 2023

Wainua (eplontersen) granted first US FDA approval

December 22, 2023

AstraZeneca to acquire Icosavax

December 12, 2023

Discontinuation of two CRYSTALIZE evidence trials

December 1, 2023

Truqap approved in US for HR+ breast cancer

November 17, 2023

Update on PACIFIC-2 Phase III trial for Imfinzi

November 14, 2023

Imfinzi combination improves PFS in liver cancer

November 9, 2023

Agreement with Eccogene for clinical stage GLP-1RA

November 9, 2023

9M and Q3 2023 results

November 9, 2023

AstraZeneca cell & gene therapy deal w/ Cellectis

November 1, 2023

AstraZeneca settles Nexium liability litigations

October 3, 2023

Dato-DXd improved PFS in breast cancer

September 22, 2023

Alexion completes Pfizer gene therapy agreement

September 20, 2023

Enhertu recommended in EU for HER2-mutant NSCLC

September 15, 2023

Fasenra Phase III EGPA trial met primary endpoint

September 11, 2023

Update on US review of Ultomiris for NMOSD

September 6, 2023

Alexion enters gene therapy agreement with Pfizer

July 28, 2023

Beyfortus approved in US for infant RSV prevention

July 17, 2023

Dato-DXd significantly improved PFS in lung cancer

July 3, 2023

nirsevimab recommended for infant RSV protection

June 9, 2023

AstraZeneca agreement with Quell Therapeutics

June 9, 2023

Imfinzi improved pCR in gastric and GEJ cancers

June 2, 2023

Lynparza approved in US for BRCAm prostate cancer

June 1, 2023

Imfinzi + Lynparza prolonged PFS in endometrial ca

May 26, 2023

Tagrisso plus chemo improved PFS in lung cancer

May 17, 2023

Farxiga extended in the US for heart failure

May 9, 2023

ODAC vote on Lynparza combo in prostate cancer

May 2, 2023

Board Committee Changes

April 27, 2023

Update to arrangements with Sobi and Sanofi

April 11, 2023

Lynparza + Imfinzi met endpoint in ovarian cancer

April 5, 2023

Ultomiris recommended for NMOSD EU approval

April 3, 2023

AstraZeneca completes KYM agreement for CMG901

March 30, 2023

Imfinzi improved EFS in resectable lung cancer

March 9, 2023

Enhertu DESTINY-PanTumor02 shows positive results

March 6, 2023

AstraZeneca prices a $2.25bn bond offering

March 1, 2023

AstraZeneca prices a EUR1.5bn bond offering

February 24, 2023

AstraZeneca acquires CinCor for cardiorenal asset

February 24, 2023

AstraZeneca enters agreement with KYM for CMG901

February 23, 2023

Update on Evusheld US EUA

January 26, 2023

Acquisition of Neogene Therapeutics completed

January 16, 2023

Airsupra (PT027) approved in US for asthma

January 11, 2023

AstraZeneca acquire CinCor for cardiorenal asset

January 9, 2023

Calls in 2023

Decks in 2023